24 . September , 2018 - Monday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Medroxyprogesterone Acetate

Big Image Pronouncation: (meh-DROX-ee-pro-JESS-tuh-rone ASS-uh-TATE)
Class: Progestin, Contraceptive hormone

Trade Names:
- Tablets 10 mg

Trade Names:
- Tablets 10 mg

Trade Names:
- Tablets 2.5 mg
- Tablets 5 mg
- Tablets 10 mg

Trade Names:
- Injection 150 mg/mL
- Injection 400 mg/mL

Trade Names:
- Tablets 2.5 mg
- Tablets 5 mg
- Tablets 10 mg

Gen-Medroxy (Canada)
Novo-Medrone (Canada)
ratio-MPA (Canada)

Mechanism of Action


Inhibits secretion of pituitary gonadotropins, thereby preventing follicular maturation and ovulation (contraceptive effect); inhibits spontaneous uterine contraction; transforms proliferative endometrium into secretory endometrium; produces antineoplastic effect in advanced endometrial or renal carcinoma.



T max is 2 to 4 h. Food increases the bioavailability of medroxyprogesterone acetate.


Medroxyprogesterone protein binding is approximately 90%.


Medroxyprogesterone is extensively metabolized in the liver by hydroxylation with subsequent conjugation. At least 16 metabolites have been identified.


Most of the metabolites are excreted in urine. The t ½ is approximately 12 h.

Special Populations

Hepatic Function Impairment

Metabolism and Cl are decreased in patients with hepatic function impairment. Lower doses or less frequent administration is recommended in patients with mild to moderate hepatic function impairment and is contraindicated in patients with severe hepatic function impairment.

Indications and Usage


Treatment of secondary amenorrhea and abnormal uterine bleeding caused by hormonal imbalance; reduction of incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogen 0.625 mg.


Prevention of pregnancy; adjunctive and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma.


Hypersensitivity to progestins; current or history of thrombophlebitis, thromboembolic disorders, cerebrovascular disease, or cerebral hemorrhage; impaired liver function; breast or genital organ cancer; undiagnosed vaginal bleeding; missed abortion; diagnostic test for pregnancy; known or suspected pregnancy.

Dosage and Administration

Abnormal Uterine Bleeding

PO 5 to 10 mg/day for 5 to 10 days beginning on 16th or 21st day of menstrual cycle.


IM 150 mg every 3 mo.

Endometrial or Renal Carcinoma
Adults Initial

IM 400 to 1,000 mg/wk.


IM 400 mg/mo.

Reduction of Endometrial Hyperplasia

PO 5 to 10 mg daily for 12 to 14 consecutive days per month, beginning on the 1st or 16th day of cycle.

Secondary Amenorrhea

PO 5 to 10 mg/day for 5 to 10 days.

General Advice

  • Injection
  • For IM injection only. Not for intradermal, subcutaneous, or intra-arterial administration.
  • Shake vial vigorously just before use to ensure that dose is being administered as a uniform suspension.
  • Do not administer if particulate matter, cloudiness, or discoloration is noted.
  • Administer by deep IM injection into gluteal or deltoid muscle. Rotate injection sites.
  • When using as contraceptive, administer prescribed dose during first 5 days after the onset of a normal menstrual period, within 5 days postpartum if not breast-feeding, or if breast-feeding, at 6 wk postpartum.


Store tablets and injection at controlled room temperature (68° to 77°F).

Drug Interactions


May increase metabolism and decrease effect of medroxyprogesterone.

Laboratory Test Interactions

Endocrine, coagulation (increased amounts of some clotting factors), thyroid, and LFT results may be affected by progestins; may decrease glucose tolerance; decreased plasma and urinary steroid levels; decreased gonadotropin levels; decreased sex-hormone-binding-globulin concentrations.

Adverse Reactions


Thrombophlebitis; edema.


Depression; headache; nervousness; dizziness; insomnia; fatigue; somnolence.


Rash; acne; melasma; chloasma; alopecia; hirsutism; photosensitivity; pruritus; urticaria.


Abdominal pain or discomfort; nausea.


Breakthrough bleeding; spotting; change in menstrual flow; amenorrhea; decrease in libido; changes in cervical erosion and secretions.


Cholestatic jaundice.


Pulmonary embolism.


Breast tenderness; masculinization of female fetus; edema; weight changes, especially weight gain; anaphylactoid reactions; bone mineral density changes, increasing risk of osteoporosis; hyperglycemia; pyrexia; galactorrhea.



Category X .


Excreted in breast milk.


Safety and efficacy not established.


May prolong contraceptive effect, which may delay time to potential conception once therapy is discontinued.


If period between injections is longer than 14 days, determine that patient is not pregnant before administering drug.

Fluid retention

Use with careful observation when conditions that might be affected by this factor are present (eg, asthma, cardiac or renal dysfunction, epilepsy).

Mental depression

Carefully observe patients with history of depression.

Ophthalmic effects

Discontinue medication if there are any sudden changes in vision, sudden onset of proptosis, diplopia, migraine, papilledema, or retinal vascular lesions.

Prolonged use

Effect of prolonged use on pituitary, ovarian, adrenal, hepatic, and uterine function not known.


Discontinue if occurring or suspected.

Vaginal bleeding

With irregular vaginal bleeding, including breakthrough bleeding, nonfunctional causes should be considered and adequate diagnostic measures undertaken.

Patient Information

  • Advise patient to read patient information leaflet before using the first time and with each refill.
  • Instruct diabetic patient taking estrogen and medroxyprogesterone to monitor blood glucose more frequently when therapy is started and to inform health care provider of significant changes in readings.
  • Teach patient proper method of breast self-examination, and remind patient to perform monthly.
  • Instruct patient to immediately report any of the following symptoms to health care provider: pain in groin or calves; sharp chest pain, coughing blood, or sudden shortness of breath; crushing chest pain or heaviness in chest; abnormal vaginal bleeding; breast lumps; sudden severe headache; dizziness or fainting; tremors or seizure; vision or speech problems; weakness or numbness of arms or legs; severe abdominal pain; depression; yellowing of the skin or eyes; persistent pain, pus, or bleeding at injection site.
  • Advise patient that follow-up visits and examinations, including Pap smear, at least once a year, will be required to monitor therapy and to keep appointments.
  • Tablets
  • Advise patient to take each dose without regard to meals but to take with food if stomach upset occurs.
  • Injection
  • Advise patient that injection will be prepared and administered by a health care provider in a medical setting.
  • Advise patient that menstrual cycle may be disrupted (eg, irregular or unpredictable bleeding, or spotting) but that this usually decreases over several months to the point of no menstrual flow. Advise patient to notify health care provider if abnormal bleeding persists or is severe.
  • Advise patient that contraceptive injection does not protect against HIV infection and other sexually transmitted diseases.

Recent Drug Updates at DrugIndexOnline:

Atropine and Phenobarbital Atropine and Phenobarbital
Some commonly used brand names are: In the U.S.— Antrocol 2 Barbidonna 1 Barbidonna No. 2 1 Barophen 1 Bellalphen 1 Butibel 3 Donnamor 1 Donnapine 1 Donnatal 1 Donnatal Extentabs 1 Donnatal No. 2 1 Donphen 1 Hyosophen 1 Kinesed 1 Malatal 1 Relaxadon 1 Spaslin 1 Spasmolin 1 Spasmophen 1 Sp more...

Caelyx Caelyx
Some commonly used brand names are: In the U.S.— Doxil In Canada— Caelyx Category Antineoplastic Description Liposomal doxorubicin (LIP-oh-som-al dox-oh-ROO-bi-sin) belongs to the general group of medicines known as antineoplastics. It is used to treat some kinds of cance more...

Dentocaine Dental Dentocaine Dental
Some commonly used brand names are: In the U.S.— Anbesol, Baby 1 Anbesol Maximum Strength Gel 1 Anbesol Maximum Strength Liquid 1 Anbesol Regular Strength Gel 3 Anbesol Regular Strength Liquid 3 Benzodent 1 Chloraseptic Lozenges 2 Chloraseptic Lozenges, Children's 1 Dentapaine 1 Dent-Zel- more...

diphtheria, haemophilus influenzae, pertussis, and tetanus vaccines diphtheria, haemophilus influenzae, pertussis, and tetanus vaccines
Generic Name: diphtheria, haemophilus influenzae, pertussis, and tetanus vaccine (dif THEER ee a, hem OFF il us in floo ENZ uh per TUS is , and TET a nus) Brand Names: ActHIB with DPT, Trihibit What is diphtheria, haemophilus influenzae, pertussis, and tetanus vaccine? Diphtheria, haemo more...

Levothroid Levothroid
Some commonly used brand names are: In the U.S.— Armour Thyroid 5 Cytomel 2 Levo-T 1 Levothroid 1 Levoxyl 1 Synthroid 1 Thyrar 5 Thyroid Strong 5 Thyrolar 3 Triostat 2 Westhroid 5 In Canada— Cytomel 2 Eltroxin 1 PMS-Levothyroxine Sodium 1 Synthroid 1 Note: For quick referenc more...

Metopirone Metopirone
Generic Name: metyrapone Dosage Form: Capsules T2005-01      Metopirone®      metyrapone USP      Capsules      Diagnostic Test of Pituitary      Adrenocorticotropic more...

Norgestimate and Ethinyl Estradiol Norgestimate and Ethinyl Estradiol
Some commonly used brand names are: In the U.S.— Alesse 3 Brevicon 5 Cyclessa 1 Demulen 1/35 2 Demulen 1/50 2 Desogen 1 Estrostep 4 Estrostep Fe 4 Genora 0.5/35 5 Genora 1/35 5 Genora 1/50 6 Intercon 0.5/35 5 Intercon 1/35 5 Intercon 1/50 6 Jenest 5 Levlen 3 Levlite 3 Levora 0.15/30 3 Loe more...

Piroxicam Piroxicam
Dosage Form: Capsules Cardiovascular Risk NSAIDs11 may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascul more...